Korean Journal of Clinical Pharmacy (한국임상약학회지)

Korean College Of Clinical Pharmacy (한국임상약학회)
권호 표지
DOI QR코드

DOI QR Code

Cancer Risk in Patients with Type 2 Diabetes on Antidiabetic Monotherapy: A Population Based Cohort Study Using National Insurance Health Service Database

혈당강하제 단독요법 투여 당뇨병환자에서 암발생률 평가: 후향적 코호트 연구

  • Received : 2019.08.01
  • Accepted : 2019.08.24
  • Published : 2019.09.30
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Diabetes is associated with cancer risk in the aging population. Observational studies have indicated the beneficial effects of metformin against breast cancer, making studies on the anticancer potential of antidiabetic drugs worthwhile. This study investigated cancer incidence in patients on antidiabetic monotherapy. Methods: Using National Health Insurance Service data (2002-2013), a retrospective cohort study that included type 2 diabetes mellitus (T2DM) patients was conducted. Study subjects were enrolled if they were ${\geq}30$ years old, on monotherapy for diabetes, and cancer-free. They were followed up for cancer occurrence or death, until December 31st, 2013. A Cox proportional hazard model analysis was conducted between metformin and sulfonylurea (including meglitinide) users, to determine cancer risk, with adjustment for age, gender, comorbidity index, dyslipidemia, hypertension, and T2DM duration. Results: The number of antidiabetic monotherapy-treated T2DM patients without a history of cancer was 9,554 (metformin, n = 5,825; sulfonylurea, n = 3,225; others, n = 504). During the follow-up period (mean, 2.04; IQR, 3.18 years), the cancer incidence rate was 5.48/100 and 5.45/100 patient-years for metformin and sulfonylurea, respectively. The hazard ratio (HR) for risk of cancer incidence in the metformin group was 0.74 (95% confidence interval [CI], 0.66-0.83; p < 0.0001), compared with sulfonylurea. Additionally, the HRs for risks of lung, liver, and stomach cancer were respectively 0.46 (95% CI, 0.31-0.66; p < 0.0001), 0.41 (95% CI, 0.31-0.54; p < 0.0001), and 0.51 (95% CI, 0.35-0.73; p = 0.0003). Conclusion: Antidiabetic therapy with metformin reduces cancer risk by 26%, specifically for lung, liver, and stomach cancer.

Keywords

References

  1. Jee SH, Ohrr H, Sull JW, Yun JE, Ji M, Samet JM. Fasting serum glucose level and cancer risk in korean men and women. JAMA 2005;293(2):194-202. https://doi.org/10.1001/jama.293.2.194
  2. Vigneri P, Frasca F, Sciacca L, Pandini G, Vigneri R. Diabetes and cancer. Endocr Relat Cancer 2009;16(4):1103-23. https://doi.org/10.1677/ERC-09-0087
  3. Hsu IR, Kim SP, Kabir M, Bergman RN. Metabolic syndrome, hyperinsulinemia, and cancer. Am J Clin Nutr 2007;86(3):867S-71S. https://doi.org/10.1093/ajcn/86.3.867S
  4. Bowker SL, Majumdar SR, Veugelers P, Johnson JA. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 2006;29(2):254-8. https://doi.org/10.2337/diacare.29.02.06.dc05-1558
  5. Chen YC, Kok VC, Chien CH, Horng JT, Tsai JJ. Cancer risk in patients aged 30 years and above with type 2 diabetes receiving antidiabetic monotherapy: A cohort study using metformin as the comparator. Ther Clin Risk Manag 2015;11:1315-23. https://doi.org/10.2147/TCRM.S91513
  6. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. BMJ 2005;330(7503):1304-5. https://doi.org/10.1136/bmj.38415.708634.F7
  7. Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD, Evans JM. New users of metformin are at low risk of incident cancer: A cohort study among people with type 2 diabetes. Diabetes Care 2009;32(9):1620-5. https://doi.org/10.2337/dc08-2175
  8. Ruiter R, Visser LE, van Herk-Sukel MP, et al. Lower risk of cancer in patients on metformin in comparison with those on sulfonylurea derivatives: Results from a large population-based follow-up study. Diabetes Care 2012;35(1):119-24. https://doi.org/10.2337/dc11-0857
  9. Thakkar B, Aronis KN, Vamvini MT, Shields K, Mantzoros CS. Metformin and sulfonylureas in relation to cancer risk in type II diabetes patients: A meta-analysis using primary data of published studies. Metab Clin Exp 2013;62(7):922-34. https://doi.org/10.1016/j.metabol.2013.01.014
  10. Shaw RJ, Lamia KA, Vasquez D, et al. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 2005;310(5754):1642-6. https://doi.org/10.1126/science.1120781
  11. Rena G, Hardie DG, Pearson ER. The mechanisms of action of metformin. Diabetologia 2017;60(9):1577-85. https://doi.org/10.1007/s00125-017-4342-z
  12. Del Barco S, Vazquez-Martin A, Cufi S, et al. Metformin: Multi-faceted protection against cancer. Oncotarget 2011;2(12):896-917. https://doi.org/10.18632/oncotarget.387
  13. Suissa S and Azoulay L. Metformin and the risk of cancer: Time-related biases in observational studies. Diabetes Care 2012;35(12):2665-73. https://doi.org/10.2337/dc12-0788
  14. Chae YK, Arya A, Malecek MK, et al. Repurposing metformin for cancer treatment: Current clinical studies. Oncotarget 2016;7(26):40767-80. https://doi.org/10.18632/oncotarget.8194
  15. Eikawa S, Nishida M, Mizukami S, Yamazaki C, Nakayama E, Udono H. Immune-mediated antitumor effect by type 2 diabetes drug, metformin. Proc Natl Acad Sci USA 2015;112(6):1809-14. https://doi.org/10.1073/pnas.1417636112
  16. Bodmer M, Becker C, Jick SS, Meier CR. Metformin does not alter the risk of lung cancer: A case-control analysis. Lung Cancer 2012;78(2):133-7. https://doi.org/10.1016/j.lungcan.2012.08.010
  17. Zhang Z, Bi Y, Li S, et al. Reduced risk of lung cancer with metformin therapy in diabetic patients: A systematic review and meta-analysis. Am J Epidemiol 2014;180(1):11-4. https://doi.org/10.1093/aje/kwu124
  18. Zhang Z, Zheng Z, Shi R, Su Q, Jiang Q, Kip KE. Metformin for liver cancer prevention in patients with type 2 diabetes: A systematic review and meta-analysis. The Journal of Clinical Endocrinology & Metabolism 2012;97(7):2347-53. https://doi.org/10.1210/jc.2012-1267
  19. Valent F. Diabetes mellitus and cancer of the digestive organs: An italian population-based cohort study. J Diabetes Complications 2015;29(8):1056-61. https://doi.org/10.1016/j.jdiacomp.2015.07.017
  20. Lee M, Hsu C, Wahlqvist ML, Tsai H, Chang Y, Huang Y. Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in taiwanese: A representative population prospective cohort study of 800,000 individuals. BMC Cancer 2011;11(1):20. https://doi.org/10.1186/1471-2407-11-20
  21. Tseng CH. Metformin reduces gastric cancer risk in patients with type 2 diabetes mellitus. Aging (Albany NY) 2016;8(8):1636-49. https://doi.org/10.18632/aging.101019